Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
INTRAVENOUS CANGRELOR INFUSION IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: PRELIMINARY RESULTS OF THE ICARUS REGISTRY
Anno:
2023
Aims: To investigate the prevalence of high bleeding risk (HBR) criteria and compare clinical outcomes between HBR and non-HBR patients receiving cangrelor in the peri-percutaneous coronary intervention (PCI) phase. Methods: Consecutive patients treated with cangrelor in 7 Italian institutions were retrospectively enrolled in the ICARUS (“Intravenous CAngrelor in high-bleeding…
Leggi di più
INTRAVENOUS CANGRELOR INFUSION IN ELDERLY PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY
Anno:
2023
Aims: To assess the clinical characteristics and compare in-hospital outcomes of elderly and non-elderly patients receiving cangrelor in the peri-percutaneous coronary intervention (PCI) phase. Methods: Consecutive patients treated with cangrelor in 7 Italian institutions were retrospectively enrolled in the ICARUS (“Intravenous CAngrelor in high-bleeding Risk patients Undergoing percutaneouS coronary…
Leggi di più
INTRAVENOUS CANGRELOR INFUSION IN PATIENTS UNDERGOING COMPLEX VERSUS NON-COMPLEX PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY
Anno:
2023
Aims: To compare the clinical characteristics and in-hospital outcomes of patients undergoing complex vs. non-complex percutaneous coronary intervention (PCI) with peri-procedural use of cangrelor. Methods: Consecutive patients treated with cangrelor in 6 Italian institutions were retrospectively enrolled in the ICARUS (“Intravenous CAngrelor in high-bleeding Risk patients Undergoing percutaneouS coronary…
Leggi di più
C69
EFFICACIA E SICUREZZA DI DISTINTI REGIMI DI TERAPIA ANTIAGGREGANTE DOPO LA PROCEDURA DI CHIUSURA PERCUTANEA DELL'AURICOLA SINISTRA: UN'ESPERIENZA REAL-WORLD
Anno:
2022
La chiusura percutanea dell'auricola sinistra(LAAO) è una procedura efficace per prevenire gli eventi tromboembolici nei pazienti con fibrillazione atriale (AF) in assenza di stenosi mitralica/protesi valvolari e con controindicazioni alla terapia anticoagulante orale (OAC). La terapia antiaggregante(APT) è necessaria dopo l'impianto per device per prevenire la formazione di trombi(DRT). Studi precedenti hanno fornito…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram